Home/Pipeline/Undisclosed Target

Undisclosed Target

Not Disclosed

DiscoveryActive

Key Facts

Indication

Not Disclosed

Phase

Discovery

Status

Active

Company

Libra Therapeutics

About Libra Therapeutics

Libra Therapeutics is a private, preclinical-stage biotech targeting neurodegenerative diseases through the modulation of lysosomal function and autophagy. Its core strategy involves a proprietary Lysofunction screening platform to identify compounds that enhance these cellular clearance pathways, with programs focused on TRPML1 activation and targeting the C9orf72 genetic mutation. The company is led by a team with deep neuroscience and drug development experience and is backed by a syndicate of life science venture capital firms.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Frontotemporal Dementia Alzheimer's Disease Parkinson's Disease Huntington's Disease

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
SRSD101	Sirius Therapeutics	Phase 1	Active